The 2021 STHLM3-MRI screening trial reported a 67% reduction in the detection of clinically nonsignificant prostate cancer and a 17% increase in detection of clinically significant cases compared with PSA and systematic biopsy [10]. This evidence concerns the gene KLK3 and prostate cancer.